Makary

The FDA blocked a melanoma drug due to confusion under Makary's leadership. A clinical trial showed that a third of patients had tumors shrink while taking RP1, a genetically engineered treatment. The trial results were promising despite the FDA blockage.

Makary is departing and his policies are being discussed, Kyle Diamantas is his acting replacement, and FDA reporter Lizzy Lawrence is providing insight on the topic.

Trump announced Makary's departure as FDA commissioner due to internal dysfunction and backlash from the industry and White House. Makary's tenure was marked by leadership turmoil and regulatory decision disputes. The move follows significant criticism from drugmakers and physicians.